History of thromboembolic or cerebrovascular events ?  months prior to starting study treatment, including transient ischemic attacks, cerebrovascular accidents, deep vein thrombosis or pulmonary emboli
History of arterial thrombotic or embolic events (within  months prior to study entry)
Subjects with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks) deep vein thrombosis or pulmonary embolism within  months of start of study registration
History of thromboembolic or cerebrovascular events ?  months prior to starting study treatment, including transient ischemic attacks, cerebrovascular accidents, deep vein thrombosis or pulmonary emboli.
Subjects with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident, deep vein thrombosis or pulmonary embolus within  months of informed consent
Subjects with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks) deep vein thrombosis or pulmonary embolism within  months of start of study treatment within  months of informed consent
Subjects with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks) deep vein thrombosis or pulmonary embolism within  months of start of study treatment within  months of informed consent
Subjects with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks) or deep venous thrombosis (DVT) within  months of informed consent\r\n* Tumor or bland thrombus in hepatic vasculature is not a contraindication provided hepatic function criteria are met
Significant thrombotic or embolic events within  weeks prior to study day ; significant thrombotic or embolic events include but are not limited to stroke or transient ischemic attack (TIA); catheter-related thrombosis is not a cause for exclusion; diagnosis of deep vein thrombosis or pulmonary embolism is allowed if it occurred >  weeks prior to study day  and the patient is asymptomatic and stable on anti-coagulation therapy
FOR ALL PHASES (Ib AND II): Arterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within  months before the start of study medication
Subjects diagnosed with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks) deep vein thrombosis or pulmonary embolism within  months of start of study treatment
Thrombotic or embolic events;
Thrombotic, embolic, venous or arterial events, such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within  months of informed consent
Arterial thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), or venous pulmonary embolism within  months before the start of study treatment; venous thrombotic events such as deep vein thrombosis within  months before the start of study treatment
Arterial thrombotic or embolic events such as cerebrovascular accident (including ischemic attacks) or hemoptysis within  months before the first dose of study drug.
Thrombotic or embolic events such as a cerebrovascular accident including transient ischemic, attacks, deep vein thrombosis (DVT) within the past  months
SORAFENIB\r\n* Major surgery, open biopsy, or significant traumatic injury within  days\r\n* Non-healing wound, ulcer, or bone fracture\r\n* Thrombotic or embolic venous or arterial events, such as cerebrovascular accident, including transient ischemic attacks, arterial thrombosis, deep vein thrombosis and pulmonary embolism within the past  months\r\n* Upper Extremity/Line associated DVTs which are adequately treated (line removed and/or patient anticoagulated) are eligible\r\n* Uncontrolled hypertension\r\n* Active bleeding during screening\r\n* Hypersensitivity to sorafenib
Significant thrombotic or embolic events within  months prior to study day ; significant thrombotic or embolic events include but are not limited to stroke or transient ischemic attack (TIA); catheter-related thrombosis is not a cause for exclusion; diagnosis of deep vein thrombosis or pulmonary embolism is allowed if the patient is clinically stable and has completed or is on stable anti-coagulation therapy
Arterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within the  months before enrollment
Any documented history of clinically identifiable thrombotic, embolic, venous, or arterial events such as cerebrovascular accident, transient ischemic attack, deep vein thrombosis, or pulmonary embolism within  months prior to initiating study treatment\r\n* Note: Patients with an asymptomatic catheter-related thrombus or a tumor-associated thrombus of locally-involved vessels or with incidental asymptomatic filling defects identified on imaging are not excluded
Subjects with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks) deep vein thrombosis or pulmonary embolism within  months of start of study treatment
Any documented history of thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident, transient ischemic attack, deep vein thrombosis, or pulmonary embolism within  months prior to initiating study treatment\r\n* Note: patients with a tumor-associated thrombus of locally-involved vessels should not be excluded from participating in the study
Thrombotic or embolic events such as a cerebrovascular accident including transient ischemic attacks within the past  months
Arterial thrombotic or embolic events such as a myocardial infarction or cerebrovascular accident (including transient ischemic attacks) within the  months prior to initiation of treatment; incidental clinically insignificant embolic phenomena that do not require anti-coagulants are not excluded; also, tumor-associated thrombus of locally-involved vessels does not count as an exclusion criterion
Sorafenib\r\n* Major surgery, open biopsy, or significant traumatic injury within  days\r\n* Non-healing wound, ulcer, or bone fracture\r\n* Thrombotic or embolic venous or arterial events, such as cerebrovascular accident, including transient ischemic attacks, arterial thrombosis, deep vein thrombosis and pulmonary embolism within the past  months\r\n* Uncontrolled hypertension\r\n* Active bleeding during screening\r\n* Hypersensitivity to sorafenib
Thrombolic or embolic events (except deep vein thrombosis [DVT] or pulmonary embolus) such as a cerebrovascular accident including transient ischemic attacks within the past  months
Arterial or venous thrombotic events or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within  months before randomization
Subjects with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks) deep vein thrombosis or pulmonary embolism within  months of start of study treatment
Any documented history of clinically significant thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident, transient ischemic attack, deep vein thrombosis, or pulmonary embolism necessitating therapeutic anticoagulation within  months prior to initiating study treatment; Note: Patients with a tumor-associated thrombus of locally-involved vessels should not be excluded from participating in the study
Arterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within  months before registration
Patients with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks) deep vein thrombosis or pulmonary embolism within  months of the study registration
Significant thrombotic or embolic events within  months prior to study day ; significant thrombotic or embolic events include but are not limited to stroke or transient ischemic attack (TIA); catheter-related thrombosis is not a cause for exclusion; diagnosis of deep vein thrombosis or pulmonary embolism is allowed if it occurred >  months prior to study day  and the patient has completed or is on stable anti-coagulation therapy
Patients with a history of thrombotic or embolic events within the last six months such as a cerebrovascular accident (including transient ischemic attacks), pulmonary embolism
Patients with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks [TIAs]) within  months before randomization
Arterial or venous thrombotic or embolic events such as cerebral vascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within  months before randomization (except for adequately treated catheter-related venous thrombosis occurring within  months before randomization).
Thrombolic or embolic events such as a cerebrovascular accident including transient ischemic attacks within the past  months
Subjects with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis, or pulmonary embolism within  months of start of study treatment.
Any history of thrombotic cerebrovascular accident or other arterial thrombosis
Thrombotic or embolic events such as a cerebrovascular accident including transient ischemic attacks within the past  months
History of thromboembolic or cerebrovascular events =<  months prior to starting study treatment, including transient ischemic attacks, cerebrovascular accidents, deep vein thrombosis or pulmonary emboli
Subjects with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks) deep vein thrombosis or pulmonary embolism within  months of study treatment start
Subjects with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks) deep vein thrombosis or pulmonary embolism within  months of informed consent
Arterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism =<  months prior to randomization
Significant thrombotic or embolic events within  weeks prior to study day ; significant thrombotic or embolic events include but are not limited to stroke or transient ischemic attack (TIA); catheter-related thrombosis is not a cause for exclusion; diagnosis of deep vein thrombosis or pulmonary embolism is allowed if it occurred >  weeks prior to study day  and the patient is asymptomatic and stable on anti-coagulation therapy
Subjects with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks) deep vein thrombosis or pulmonary embolism =<  months prior to registration
Arterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within the  months before start of study medication (except for adequately treated catheter-related venous thrombosis occurring more than  month before the start of study medication)
Subjects with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks) deep vein thrombosis or pulmonary embolism within  months of informed consent
Subjects with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks) deep vein thrombosis or pulmonary embolism within  months of start of study treatment
Thrombolic or embolic events such as a cerebrovascular accident including transient ischemic attacks within the past  months
History of arterial thrombotic or embolic events (within  months prior to study entry)
Subjects with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks) within  months of informed consent
Subjects with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks) within  months of informed consent
Arterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within  months before the start of study medication.
Arterial thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), or pulmonary embolism within the  months before start of FOLFIRI
Thrombolic or embolic events such as a cerebrovascular accident including transient ischemic attacks within the past  months
Thrombolic or embolic events such as a cerebrovascular accident including transient ischemic attacks within the past  months; hepatic portal vein thrombus is not considered an exclusion criterion
Thrombotic or embolic events such as cerebrovascular accident, deep vein thrombosis or pulmonary embolism. History of transient ischemic attack is allowed.
Subjects with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within  months of study registration.
Arterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within the  months before start of study medication (except for adequately treated catheter-related venous thrombosis occurring more than  month before the start of study medication).
Arterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within  months before start of study treatment. However, if a patient has recovered to ECOG performance status of ?  he/she may be enrolled provided that other eligibility criteria are met
Subjects with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks) deep vein thrombosis or pulmonary embolism within  months of start of study treatment
Subjects with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks) deep vein thrombosis or pulmonary embolism within  months of start of study treatment
Subjects with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks) deep vein thrombosis or pulmonary embolism that have initiated within  months of start of study treatment; stable, persistent events under appropriate management diagnosed >  months prior to treatment are allowed at the discretion of the investigator
Arterial or venous thrombotic or embolic events
Have had arterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis, or pulmonary embolism within  months prior to the initiation of study treatment.
Thrombotic or embolic events such as a cerebrovascular accident including transient ischemic attacks within the past  months
History of arterial or venous thrombotic/embolic events =<  months prior to registration
Arterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within  months before the start of study medication
Subjects with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within  months of informed consent; Note: subjects with recent deep vein thrombosis (DVT) who have been treated with therapeutic anticoagulating agents for at least  weeks prior to study treatment are eligible
Thrombolytic, embolic, venous, or arterial events such as cerebrovascular accident including transient ischemic attacks within the past  months
Thrombolic or embolic events such as a cerebrovascular accident including transient ischemic attacks within the past  months
Thrombotic or embolic events such as a cerebrovascular accident including transient ischemic attacks within the past  months
Thrombolic or embolic events such as a cerebrovascular accident including transient ischemic attacks within the past  months
Thrombotic or embolic events such as a cerebrovascular accident including transient ischemic attacks within the past  months
Have had arterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis, or pulmonary embolism within  months prior to the initiation of study treatment
Subjects with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks) deep vein thrombosis or pulmonary embolism within  months of start of study treatment within  months of informed consent
